Fadi Salah Issa, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
T-Lymphocytes, Regulatory | 22 | 2024 | 3092 | 4.300 |
Why?
|
Organ Transplantation | 12 | 2023 | 1165 | 3.010 |
Why?
|
Transplantation Tolerance | 11 | 2021 | 620 | 2.860 |
Why?
|
Graft Rejection | 15 | 2024 | 4481 | 2.170 |
Why?
|
Immune Tolerance | 13 | 2023 | 2307 | 1.210 |
Why?
|
Immunosuppressive Agents | 9 | 2024 | 4190 | 1.010 |
Why?
|
Kidney Transplantation | 4 | 2024 | 4242 | 0.940 |
Why?
|
Tacrolimus | 2 | 2024 | 736 | 0.880 |
Why?
|
Living Donors | 2 | 2024 | 643 | 0.820 |
Why?
|
Monitoring, Immunologic | 1 | 2021 | 99 | 0.730 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2058 | 0.680 |
Why?
|
Graft Survival | 10 | 2024 | 3843 | 0.680 |
Why?
|
Disasters | 5 | 2023 | 520 | 0.680 |
Why?
|
Cell Transplantation | 1 | 2021 | 472 | 0.640 |
Why?
|
T-Lymphocyte Subsets | 3 | 2018 | 1803 | 0.630 |
Why?
|
Awards and Prizes | 3 | 2017 | 362 | 0.620 |
Why?
|
Relief Work | 4 | 2024 | 130 | 0.610 |
Why?
|
Interleukins | 1 | 2023 | 782 | 0.600 |
Why?
|
Isoantigens | 1 | 2020 | 559 | 0.600 |
Why?
|
Skin Transplantation | 5 | 2020 | 1091 | 0.600 |
Why?
|
Autoimmune Diseases | 2 | 2024 | 2244 | 0.580 |
Why?
|
bcl-X Protein | 1 | 2019 | 410 | 0.570 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2021 | 5666 | 0.570 |
Why?
|
Models, Animal | 2 | 2021 | 2114 | 0.560 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2018 | 346 | 0.540 |
Why?
|
Lymphocyte Activation | 5 | 2023 | 5478 | 0.520 |
Why?
|
Terrorism | 3 | 2023 | 210 | 0.480 |
Why?
|
Transplantation, Homologous | 5 | 2023 | 4822 | 0.480 |
Why?
|
Gold | 1 | 2018 | 482 | 0.450 |
Why?
|
Writing | 1 | 2016 | 199 | 0.450 |
Why?
|
Kidney Diseases | 1 | 2024 | 2092 | 0.440 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 858 | 0.440 |
Why?
|
Lymphocyte Transfusion | 2 | 2011 | 232 | 0.430 |
Why?
|
Immunomodulation | 2 | 2019 | 548 | 0.410 |
Why?
|
Disaster Medicine | 2 | 2023 | 71 | 0.400 |
Why?
|
Hematopoiesis | 1 | 2021 | 2049 | 0.380 |
Why?
|
Disaster Planning | 3 | 2023 | 557 | 0.380 |
Why?
|
Earthquakes | 2 | 2024 | 191 | 0.370 |
Why?
|
Biomedical Research | 2 | 2017 | 3434 | 0.370 |
Why?
|
Pneumonia | 1 | 2023 | 2142 | 0.370 |
Why?
|
Information Storage and Retrieval | 1 | 2016 | 820 | 0.360 |
Why?
|
Mass Casualty Incidents | 2 | 2022 | 179 | 0.340 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4574 | 0.340 |
Why?
|
Organizations | 2 | 2021 | 172 | 0.330 |
Why?
|
Animals | 29 | 2024 | 168089 | 0.330 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 2894 | 0.320 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 8002 | 0.320 |
Why?
|
Adoptive Transfer | 4 | 2023 | 823 | 0.310 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2019 | 1852 | 0.290 |
Why?
|
Mesenchymal Stem Cells | 1 | 2018 | 1645 | 0.280 |
Why?
|
Skin Neoplasms | 2 | 2023 | 5809 | 0.280 |
Why?
|
Humans | 61 | 2024 | 761222 | 0.270 |
Why?
|
Adaptive Immunity | 1 | 2011 | 724 | 0.270 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2024 | 501 | 0.260 |
Why?
|
Emergency Medical Services | 3 | 2023 | 1920 | 0.260 |
Why?
|
T-Lymphocytes | 2 | 2023 | 10203 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3093 | 0.260 |
Why?
|
Pandemics | 5 | 2024 | 8663 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3215 | 0.260 |
Why?
|
Immunophenotyping | 3 | 2020 | 1867 | 0.260 |
Why?
|
Bone Marrow Transplantation | 2 | 2013 | 2692 | 0.250 |
Why?
|
Graft vs Host Disease | 2 | 2020 | 3025 | 0.250 |
Why?
|
Skin | 3 | 2016 | 4473 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10218 | 0.240 |
Why?
|
Melanoma | 1 | 2023 | 5694 | 0.240 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1463 | 0.240 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2023 | 4373 | 0.240 |
Why?
|
Internet | 1 | 2016 | 3096 | 0.220 |
Why?
|
Cyclonic Storms | 1 | 2024 | 116 | 0.200 |
Why?
|
Sentinel Surveillance | 1 | 2023 | 291 | 0.190 |
Why?
|
Surge Capacity | 1 | 2021 | 48 | 0.190 |
Why?
|
Gene Expression Regulation | 1 | 2019 | 11855 | 0.180 |
Why?
|
Cell Movement | 1 | 2012 | 5195 | 0.180 |
Why?
|
Sirolimus | 2 | 2018 | 1540 | 0.180 |
Why?
|
State Medicine | 1 | 2022 | 216 | 0.180 |
Why?
|
Mice, Inbred BALB C | 6 | 2020 | 6200 | 0.180 |
Why?
|
Mice | 12 | 2022 | 81330 | 0.180 |
Why?
|
Transplantation, Autologous | 1 | 2024 | 2112 | 0.170 |
Why?
|
Pennsylvania | 1 | 2020 | 612 | 0.160 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 732 | 0.160 |
Why?
|
Neck | 1 | 2023 | 734 | 0.160 |
Why?
|
Cell Differentiation | 4 | 2020 | 11512 | 0.150 |
Why?
|
Cultural Characteristics | 1 | 2019 | 250 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.150 |
Why?
|
Regenerative Medicine | 1 | 2020 | 307 | 0.140 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2020 | 548 | 0.140 |
Why?
|
Mice, Inbred NOD | 1 | 2021 | 1822 | 0.140 |
Why?
|
Wounds, Gunshot | 1 | 2022 | 582 | 0.140 |
Why?
|
HLA-DR1 Antigen | 1 | 2016 | 11 | 0.130 |
Why?
|
Organ Specificity | 1 | 2021 | 1963 | 0.130 |
Why?
|
Mice, SCID | 1 | 2021 | 2621 | 0.130 |
Why?
|
Metabolic Networks and Pathways | 1 | 2020 | 790 | 0.130 |
Why?
|
Agriculture | 1 | 2017 | 187 | 0.120 |
Why?
|
Treatment Outcome | 5 | 2024 | 64681 | 0.120 |
Why?
|
Immunocompromised Host | 1 | 2020 | 858 | 0.120 |
Why?
|
Accidents, Occupational | 1 | 2017 | 249 | 0.120 |
Why?
|
Abdominal Wall | 1 | 2016 | 166 | 0.120 |
Why?
|
Autoimmunity | 2 | 2020 | 1356 | 0.120 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 1086 | 0.120 |
Why?
|
Receptors, Interleukin-6 | 1 | 2016 | 224 | 0.120 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.110 |
Why?
|
Access to Information | 1 | 2016 | 316 | 0.110 |
Why?
|
Bibliometrics | 1 | 2017 | 352 | 0.110 |
Why?
|
Mammary Arteries | 1 | 2013 | 81 | 0.110 |
Why?
|
Cells, Cultured | 2 | 2019 | 18927 | 0.100 |
Why?
|
Altruism | 2 | 2024 | 208 | 0.100 |
Why?
|
Medicine | 1 | 2020 | 942 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2023 | 3461 | 0.100 |
Why?
|
Biological Assay | 1 | 2015 | 623 | 0.100 |
Why?
|
Vascular Grafting | 1 | 2013 | 162 | 0.100 |
Why?
|
Stem Cell Transplantation | 2 | 2020 | 1600 | 0.090 |
Why?
|
Cell Survival | 2 | 2019 | 5778 | 0.090 |
Why?
|
RNA, Messenger | 2 | 2023 | 12747 | 0.090 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2010 | 50 | 0.090 |
Why?
|
RNA Interference | 1 | 2019 | 2816 | 0.090 |
Why?
|
Immune System | 1 | 2016 | 792 | 0.090 |
Why?
|
Aorta, Abdominal | 1 | 2013 | 625 | 0.090 |
Why?
|
Emergency Medicine | 1 | 2019 | 1198 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2507 | 0.090 |
Why?
|
Forkhead Transcription Factors | 2 | 2020 | 1613 | 0.080 |
Why?
|
Histocompatibility Testing | 1 | 2010 | 716 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3354 | 0.080 |
Why?
|
Liver Transplantation | 2 | 2017 | 2332 | 0.080 |
Why?
|
Curriculum | 1 | 2021 | 3741 | 0.070 |
Why?
|
Interferon-gamma | 1 | 2016 | 3155 | 0.070 |
Why?
|
Lung | 2 | 2023 | 9979 | 0.070 |
Why?
|
Time Factors | 2 | 2024 | 39957 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9417 | 0.070 |
Why?
|
Reperfusion Injury | 1 | 2013 | 1026 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4021 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2022 | 15637 | 0.070 |
Why?
|
Fetal Blood | 1 | 2013 | 1348 | 0.070 |
Why?
|
Mice, Knockout | 2 | 2019 | 14392 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2020 | 5871 | 0.060 |
Why?
|
Signal Transduction | 2 | 2019 | 23419 | 0.060 |
Why?
|
HLA Antigens | 1 | 2010 | 1331 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2017 | 2293 | 0.060 |
Why?
|
Emergency Service, Hospital | 2 | 2021 | 7865 | 0.060 |
Why?
|
Syria | 1 | 2024 | 85 | 0.060 |
Why?
|
Turkey | 1 | 2024 | 254 | 0.060 |
Why?
|
Surgery, Plastic | 1 | 2010 | 640 | 0.060 |
Why?
|
Heart Transplantation | 1 | 2017 | 3258 | 0.060 |
Why?
|
Transplantation Immunology | 2 | 2017 | 537 | 0.050 |
Why?
|
Armenia | 1 | 2022 | 15 | 0.050 |
Why?
|
Apoptosis | 1 | 2019 | 9478 | 0.050 |
Why?
|
Jordan | 1 | 2022 | 73 | 0.050 |
Why?
|
Stem Cells | 1 | 2015 | 3517 | 0.050 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2020 | 4575 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4310 | 0.050 |
Why?
|
Asia | 1 | 2023 | 622 | 0.050 |
Why?
|
Tissue Donors | 1 | 2010 | 2335 | 0.050 |
Why?
|
Morals | 1 | 2024 | 289 | 0.050 |
Why?
|
Antigens, CD | 1 | 2011 | 4009 | 0.050 |
Why?
|
Rats, Transgenic | 1 | 2020 | 69 | 0.050 |
Why?
|
Immunotherapy, Adoptive | 1 | 2010 | 1468 | 0.050 |
Why?
|
Saudi Arabia | 1 | 2021 | 210 | 0.050 |
Why?
|
Republic of Korea | 1 | 2023 | 576 | 0.050 |
Why?
|
Phenotype | 1 | 2018 | 16575 | 0.050 |
Why?
|
Fentanyl | 1 | 2023 | 433 | 0.040 |
Why?
|
Immunotherapy | 1 | 2016 | 4642 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 424 | 0.040 |
Why?
|
Hospitals | 2 | 2024 | 3881 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2022 | 696 | 0.040 |
Why?
|
Child | 2 | 2024 | 80154 | 0.040 |
Why?
|
STAT3 Transcription Factor | 1 | 2022 | 872 | 0.040 |
Why?
|
Cohort Studies | 1 | 2020 | 41496 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 848 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1751 | 0.040 |
Why?
|
Mice, Transgenic | 2 | 2020 | 9520 | 0.040 |
Why?
|
Adult | 3 | 2024 | 221120 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2020 | 801 | 0.040 |
Why?
|
Morbidity | 1 | 2022 | 1751 | 0.040 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18222 | 0.040 |
Why?
|
Rescue Work | 1 | 2017 | 56 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2022 | 1176 | 0.030 |
Why?
|
China | 1 | 2023 | 2374 | 0.030 |
Why?
|
Species Specificity | 1 | 2020 | 2406 | 0.030 |
Why?
|
Equipment Safety | 1 | 2017 | 249 | 0.030 |
Why?
|
Obesity | 1 | 2017 | 12940 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2022 | 1783 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 934 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1747 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2023 | 80675 | 0.030 |
Why?
|
Schools | 1 | 2022 | 1483 | 0.030 |
Why?
|
Antibodies, Heterophile | 1 | 2013 | 128 | 0.030 |
Why?
|
Population Surveillance | 1 | 2023 | 2598 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 1132 | 0.030 |
Why?
|
Cold Ischemia | 1 | 2013 | 70 | 0.030 |
Why?
|
Middle Aged | 2 | 2024 | 220858 | 0.030 |
Why?
|
International Cooperation | 1 | 2019 | 1423 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2022 | 1796 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2011 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26072 | 0.020 |
Why?
|
Aged | 1 | 2024 | 169292 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3134 | 0.020 |
Why?
|
Female | 4 | 2024 | 392552 | 0.020 |
Why?
|
Cross Reactions | 1 | 2013 | 819 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2013 | 1059 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2672 | 0.020 |
Why?
|
Receptors, Fc | 1 | 2013 | 537 | 0.020 |
Why?
|
Immunity | 1 | 2015 | 996 | 0.020 |
Why?
|
Neutrophils | 1 | 2022 | 3763 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1885 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2022 | 5295 | 0.020 |
Why?
|
Male | 2 | 2024 | 360703 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3805 | 0.020 |
Why?
|
Developing Countries | 1 | 2019 | 2863 | 0.020 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2013 | 1348 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3337 | 0.020 |
Why?
|
Clinical Competence | 1 | 2021 | 4788 | 0.020 |
Why?
|
United States | 2 | 2023 | 72341 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2013 | 2381 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2022 | 20118 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7386 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 7965 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 24022 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9567 | 0.010 |
Why?
|
Adolescent | 1 | 2022 | 88300 | 0.010 |
Why?
|